Long-Acting Injectables (LAIs) Market Global Report 2026

The long-acting injectables (LAIs) market size has grown rapidly in recent years. It will grow from $13.31 billion in 2025 to $15.01 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to rising incidence of schizophrenia and bipolar disorder, increasing need for improved medication adherence systems, early-stage development of depot injection technologies, growing application of hormonal injectable contraceptives, and limited availability of long-acting sustained-release drug delivery solutions.

The long-acting injectables (LAIs) market size is expected to see rapid growth in the next few years. It will grow to $24.45 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period is driven by advancements in nano-based and polymer-based drug delivery systems, rising approvals of long-duration antiviral therapies, increasing adoption of precision medicine strategies, expansion of outpatient and home-based care models, and growing investments in extended-release injectable drug development pipelines. Key trends in the forecast period include increased use of long-acting injectable treatments for chronic psychiatric disorders, rising adoption of depot formulations to enhance patient adherence and reduce dosing frequency, development of advanced polymeric and nanotechnology-based sustained-release drug systems, expanding clinical use of long-acting antivirals in infectious disease management, and greater integration of long-acting injectables into outpatient and specialty care settings.

The increasing burden of schizophrenia is expected to propel the growth of the long-acting injectables (LAIs) market going forward. Schizophrenia is a chronic mental health disorder that affects a person’s thinking, emotions, and behavior, often causing hallucinations, delusions, and disorganized thinking. The rising burden of schizophrenia is attributed to improved mental health awareness, which leads to more individuals recognizing symptoms and seeking diagnosis. Long-acting injectables (LAIs) aid in the management of schizophrenia by ensuring consistent medication delivery over time, thereby improving treatment adherence, reducing relapse risk, and supporting better long-term symptom control. For instance, in January 2026, according to WebMD LLC, a US-based online digital health platform, schizophrenia imposed an economic burden of nearly $367 billion in the United States in 2024, affecting about 3.1 million adults. Therefore, the increasing burden of schizophrenia is driving the growth of the long-acting injectables (LAIs) market.

Key companies operating in the long-acting injectables (LAIs) market are focusing on developing innovative solutions, such as advanced sustained-release depot formulation platforms, to enable longer dosing intervals, improve patient adherence, and enhance therapeutic consistency. Advanced sustained-release depot formulation platforms are drug delivery systems that store medication in a long-acting injectable form at the injection site and release it slowly and steadily into the body over an extended period to maintain consistent therapeutic levels. For example, in November 2025, Lupin Limited, an India-based pharmaceutical company, launched risperidone long-acting injectable under its proprietary precision sphere platform, designed to provide extended drug release and improved dosing convenience with CGT exclusivity in the United States. The platform incorporates advanced polymer-based delivery technology that enables sustained release of the active ingredient over an extended duration, supports better patient compliance, and reduces relapse risk by maintaining stable therapeutic levels, marking a strategic advancement in long-acting injectable therapies for neuropsychiatric conditions.

In November 2023, Teva Pharmaceutical Industries Ltd., an Israel-based biopharmaceutical company, entered into a collaboration with Royalty Pharma to accelerate development of its olanzapine long-acting injectable (LAI) program (TEV-749) for the treatment of schizophrenia. This partnership is designed to support late-stage clinical development of the LAI formulation through non-dilutive funding in exchange for future royalty rights, thereby reducing financial exposure and accelerating time-to-market for the long-acting injectable therapy aimed at improving patient adherence through sustained drug release. Royalty Pharma Plc is a US-based biopharmaceutical royalty and investment company focused on funding innovative drug development programs in exchange for future royalty-based returns.

Major companies operating in the long-acting injectables (LAIs) market are Johnson And Johnson, Roche Holding AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, Novo Nordisk A/S, GSK plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Shionogi And Co Ltd., Dr. Reddy’s Laboratories Ltd., ViiV Healthcare, H. Lundbeck A/S, Lupin Limited, Amneal Pharmaceuticals Inc., Alkermes plc, Syngene International Limited.

North America was the dominant region in the long-acting injectables (LAIs) market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in long-acting injectables (LAIs) report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the long-acting injectables (LAIs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The long-acting injectables (LAIs) market consists of sales of paliperidone palmitate, risperidone microspheres, aripiprazole monohydrate, olanzapine pamoate, and naltrexone extended-release injectable. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The long-acting injectables (LAIs) market research report is one of a series of new reports that provides long-acting injectables (LAIs) market statistics, including long-acting injectables (LAIs) industry global market size, regional shares, competitors with a long-acting injectables (LAIs) market share, detailed long-acting injectables (LAIs) market segments, market trends and opportunities, and any further data you may need to thrive in the long-acting injectables (LAIs) industry. This long-acting injectables (LAIs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.